The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Ticlopidine and Clopidogrel
Abstract
Abstract —The thienopyridines ticlopidine and clopidogrel are inhibitors of platelet function in vivo. Their mode of action has not been defined, but it appears that they require conversion to as yet unidentified metabolites that are noncompetitive antagonists of the platelet ADP receptor. Inhibition of platelet aggregation with these compounds is delayed until 24 to 48 hours after administration. Maximum inhibition occurs after 3 to 5 days, and recovery is slow after drug withdrawal. Ticlopidine is effective in preventing cardiovascular events in cerebrovascular, cardiovascular, and peripheral vascular disease, with an efficacy that is similar to aspirin. However, its use is associated with significant and sometimes fatal adverse reactions, specifically neutropenia and bone marrow aplasia. Gastrointestinal side effects and skin rashes are common and result in discontinuation of therapy in up to 10% of patients. Clopidogrel is at least as effective as aspirin in preventing cardiovascular events in patients with a history of vascular disease. It appears to be safer than ticlopidine, although its efficacy in acute coronary syndromes or post–coronary-stent insertion has not been reported. Important outstanding issues are whether clopidogrel adds to the benefit of aspirin and whether the combination of these agents is safe. If so, this combination may become the standard for antithrombotic therapy in cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Schömig, A., Neumann, F.-J., Kastrati, A., Schühlen, H., Blasini, R., Hadamitzky, M., Walter, H., Zitzmann-Roth, E.-M., Richardt, G., Alt, E., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604253341702 · Cited by 2,028
A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting
Leon, M. B., Baim, D. S., Popma, J. J., Gordon, P. C., Cutlip, D. E., Ho, K. K. L., Giambartolomei, A., Diver, D. J., Lasorda, D. M., Williams, D. O., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392303 · Cited by 1,815
Hass, W. K., Easton, J. D., Adams, H. P., Pryse-Phillips, W., Molony, B. A., Anderson, S., Kamm, B., & for the Ticlopidine Aspirin Stroke Study Group (1989) · New England Journal of Medicine · doi:10.1056/nejm198908243210804 · Cited by 1,198
Purinoceptors: Are there families of P2X and P2Y purinoceptors?
Abbracchio, M. P., & Burnstock, G. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)00048-4 · Cited by 1,083
THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE
Gent, M., Donald Easton, J., Hachinski, V., Panak, E., Sicurella, J., Blakely, J., Ellis, D., Harbison, J., Roberts, R., & Turpie, A. G. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92327-1 · Cited by 910
Adenosine Diphosphate in Red Cells as a Factor in the Adhesiveness of Human Blood Platelets
GAARDER, A., JONSEN, J., LALAND, S., HELLEM, A., & OWREN, P. A. (1961) · Nature · doi:10.1038/192531a0 · Cited by 786
Bertrand, M. E., Legrand, V., Boland, J., Fleck, E., Bonnier, J., Emmanuelson, H., Vrolix, M., Missault, L., Chierchia, S., Casaccia, M., et al. (1998) · Circulation · doi:10.1161/01.cir.98.16.1597 · Cited by 583
Jin, J., & Kunapuli, S. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8070 · Cited by 540
Molecular Basis for ADP-induced Platelet Activation
Jin, J., Daniel, J. L., & Kunapuli, S. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.2030 · Cited by 477
Urban, P., Macaya, C., Rupprecht, H.-J., Kiemeneij, F., Emanuelsson, H., Fontanelli, A., Pieper, M., Wesseling, T., & Sagnard, L. (1998) · Circulation · doi:10.1161/01.cir.98.20.2126 · Cited by 445
Molecular Basis for ADP-induced Platelet Activation
Daniel, J. L., Dangelmaier, C., Jin, J., Ashby, B., Smith, J. B., & Kunapuli, S. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.2024 · Cited by 441
Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine: A Review of 60 Cases
Bennett, C. L., Weinberg, P. D., Rozenberg-Ben-Dror, K., Yarnold, P. R., Kwaan, H. C., & Green, D. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-7-199804010-00004 · Cited by 434
Balsano, F., Rizzon, P., Violi, F., Scrutinio, D., Cimminiello, C., Aguglia, F., Pasotti, C., & Rudelli, G. (1990) · Circulation · doi:10.1161/01.cir.82.1.17 · Cited by 386
Léon, C., Hechler, B., Vial, C., Leray, C., Cazenave, J.-P., & Gachet, C. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00022-7 · Cited by 296
Savi, P., Combalbert, J., Gaich, C., Rouchon, M.-C., Maffrand, J., Berger, Y., & Herbert, J. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648859 · Cited by 283
JANZON, L., BERGQVIST, D., BOBERG, J., BOBERG, M., ERIKSSON, I., LINDGÄRDE, F., & PERSSON, G. (1990) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1990.tb00164.x · Cited by 276
The P2Y1 Receptor Is Necessary for Adenosine 5′-Diphosphate–Induced Platelet Aggregation
Hechler, B., Léon, C., Vial, C., Vigne, P., Frelin, C., Cazenave, J.-P., & Gachet, C. (1998) · Blood · doi:10.1182/blood.v92.1.152.413k27_152_159 · Cited by 265
Role of P2Y1 purinoceptor in ADP‐induced platelet activation
Savi, P., Beauverger, P., Labouret, C., Delfaud, M., Salel, V, Kaghad, M., & Herbert, J. M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00025-8 · Cited by 197
Coukell, A. J., & Markham, A. (1997) · Drugs · doi:10.2165/00003495-199754050-00006 · Cited by 168
Dol, F., Bernat, A., Falotico, R., Lalé, A., Savi, P., & Herbert, J.-M. (1998) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615238 · Cited by 163
Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial.
BALSANO, F., COCCHERI, S., Libretti, A., Nenci, G., Catalano, M., Fortunato, G., Grasselli, S., Violi, F., Hellemans, H., & Vanhove, P. (1989) · PubMed · Cited by 135
Effect of Ticlopidine on the Long-Term Patency of Saphenous-Vein Bypass Grafts in the Legs
Becquemin, J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372404 · Cited by 133
Schömig, A., Neumann, F., Walter, H., Schühlen, H., Hadamitzky, M., Zitzmann-Roth, E.-M., Dirschinger, J., Hausleiter, J., Blasini, R., Schmitt, C., et al. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00450-0 · Cited by 131
Rupprecht, H. J., Darius, H., Borkowski, U., Voigtländer, T., Nowak, B., Genth, S., & Meyer, J. (1998) · Circulation · doi:10.1161/01.cir.97.11.1046 · Cited by 122
Makkar, R. R. (1998) · European Heart Journal · doi:10.1053/euhj.1998.1042 · Cited by 120
Platelet Anti-Aggregating Activity and Tolerance of Clopidogrel in Atherosclerotic Patients
Boneu, B., Destelle, G., & on behalf of the Study Group (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650689 · Cited by 108
Kastrati, A., Schühlen, H., Hausleiter, J., Walter, H., Zitzmann-Roth, E.-M., Hadamitzky, M., Elezi, S., Ulm, K., Dirschinger, J., Neumann, F.-J., et al. (1997) · PubMed · Cited by 92
P2X1 Purinoceptor in Human Platelets
Sun, B., Li, J., Okahara, K., & Kambayashi, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.19.11544 · Cited by 90
Steinhubl, S. R., Lauer, M. S., Mukherjee, D., Moliterno, D. J., Lincoff, A. M., Ellis, S. G., & Topol, E. J. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00376-3 · Cited by 81
Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19*
Donahue, S., Flockhart, D. A., Abernethy, D. R., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90054-0 · Cited by 73
Bergqvist, D., Almgren, B., & Dickinson, J. P. (1995) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/s1078-5884(05)80200-x · Cited by 59
Boissel, J., Peyrieux, J. C., & Destors, J. M. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646882 · Cited by 59
cAMP is not an important messenger for ADP-induced platelet aggregation
Savi, P., Pflieger, A. M., & Herbert, J. M. (1996) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-199603000-00035 · Cited by 56
A Clinical Trial Comparing Three Antithrombotic-Drug Regimens After Coronary Artery Stenting
Leon, M. B., Baim, D. S., Popma, J. J., et al. (1999) · Survey of Anesthesiology · doi:10.1097/00132586-199908000-00006 · Cited by 56
Effect of Food and Antacid on Absorption of Orally Administered Ticlopidine Hydrochloride
Shah, J. A., Fratis, A., Ellis, D. J., Murakami, S., & Teitelbaum, P. (1990) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1990.tb03635.x · Cited by 43
Ticlopidine induced cholestatic jaundice.
Yim, H. B., Lieu, P. K., & Choo, P. W. J. (1997) · PubMed · Cited by 10
Cited by
Sabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Perioperative Management of Antithrombotic Therapy
Douketis, J. D., Spyropoulos, A. C., Spencer, F. A., Mayr, M., Jaffer, A. K., Eckman, M. H., Dunn, A. S., & Kunz, R. (2012) · Chest · doi:10.1378/chest.11-2298 · Cited by 1,641
Protease‐activated receptors in hemostasis, thrombosis and vascular biology
COUGHLIN, S. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01377.x · Cited by 1,035
Patrono, C., Coller, B., Dalen, J. E., Fitz Gerald, G. A., Fuster, V., Gent, M., Hirsh, J., & Roth, G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.39s · Cited by 963
Metadata
- Authors
- Quinn, M. J., & Fitzgerald, D. J.
- Venue
- Circulation
- Published
- 1999-10-12
- Volume
- 100
- Issue
- 15
- Pages
- 1667-1672
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1976361153
- Cited by
- 496
- References
- 39
- FWCI
- 17.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.